MPLT · MapLight Therapeutics, Inc. · Metrics
$8.22
+0.06 (+0.74%)
At close · Oct 22
Return incl. dividend (before tax)
Market Cap
$378.44M
Shares
46.38M
Volume · Oct 22
70.68K
Avg daily vol (3M)
810.26K
MPLT metrics
58 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$8.16
Market cap
$378.44M
Price action
20 metricsPrice change (1W)
+4.5%
Price change (30D)
-24.9%
Price change (3M)
-76.9%
Price change (6M)
-74.6%
Price change (YTD)
-53.5%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$39.80
52-week low
$7.70
Change from 52-week high
-79.5%
Change from 52-week low
+6.0%
Annualized volatility
113.4%
Annualized volatility (3M)
168.8%
Beta
0.9
RSI (14D)
30.9
Price vs SMA 50
-25.6%
Price vs SMA 200
-60.9%
Avg volume (3M)
810,260
Relative volume
0.4
Average dollar volume
$9.93M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
46.38M
Valuation
12 metricsP / E (TTM)
0.2
Trailing earnings · reciprocal yield 578.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.1
reciprocal yield 92.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-60.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-07-27
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$242.93M
Net income (TTM)
−$229.83M
Trailing 12 months
Diluted EPS (TTM)
$47.22
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5,854.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-66.0%
Return on assets
-62.4%
Debt / equity
0.0
Current ratio
16.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
16.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$304.73M
Latest balance sheet
Cash & equivalents
$71.63M
Total assets
$368.35M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$174.67M
Capital expenditures (TTM)
$453,000
R&D (TTM)
$198.84M
SG&A (TTM)
—
Stock compensation (TTM)
$53.91M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
106
13F filer change QoQ
+25
Institutional ownership
56.7%
Conviction holders (share of 13F filers)
7.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+7.4%
Holder tenure
2.8
Price vs estimated holder cost
+89.9%
Ownership (registered funds)
1 metricsIndex-fund ownership
5.4%
Short interest
3 metricsShort interest
6.8%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
64 / 100
Insider activity
2 metricsNet insider buying (90D)
−$1.38M
Insider-sentiment score
15 / 100
Risk flags
1 metricsGoing concern
—